Skip to main content
PLIANT THERAPEUTICS, INC. logo

PLIANT THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · PLRX ISIN · US7291391057 LEI · 5493002Q5LITR7VHZH02 US Professional, scientific and technical activities
Open in API
Filings indexed 403 across all filing types
Latest filing 2023-01-26 Director's Dealing
Country US United States of America
Listing US PLRX

About PLIANT THERAPEUTICS, INC.

https://pliantrx.com/

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of fibrosis and related diseases. The company leverages its expertise in integrin biology to create tissue-specific treatments. Its therapeutic approach centers on modulating integrin activity and inhibiting TGF-β1 signaling, which are key molecular drivers of fibrosis. Pliant utilizes its proprietary discovery platform to advance a pipeline of integrin-based product candidates, aiming to provide safer and more effective therapies for patients.

Recent filings

Filing Released Lang Actions
Director's Dealing 2023
Director's Dealing
2023-01-26 English
Director's Dealing 2023
Director's Dealing
2023-01-26 English
Director's Dealing 2023
Director's Dealing
2023-01-26 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Pliant Therapeutics, Inc. It includes disclosures about a preliminary prospectus supplement related to a public offering of common stock, details about an underwriting agreement, and financial estimates for the quarter and year ended December 31, 2022. The document does not contain full financial statements or detailed financial analysis but rather announces financing activities and related agreements. The primary focus is on the public offering and underwriting agreement, which are capital raising activities. Therefore, this document fits best under the category of Capital/Financing Update (CAP). The document length (7815 characters) and content confirm it is not merely an announcement of a report but a substantive filing about financing.
2023-01-25 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a public offering of common stock by Pliant Therapeutics, Inc. It includes detailed information about the offering, underwriting, risk factors, use of proceeds, and legal matters. The document references registration numbers and SEC filing rules typical of securities offering documents. It is not a financial report, earnings release, management discussion, or any other type of corporate report. Instead, it is a capital markets document related to fundraising and issuance of shares. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is a full prospectus supplement, not a brief announcement or regulatory filing.
2023-01-25 English
S-3MEF
Regulatory Filings Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC by Pliant Therapeutics, Inc. It is a registration statement under the Securities Act of 1933, used for registering securities for public offering. The document includes details about the registration, incorporation by reference of prior filings, exhibits, and signatures. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration and offering. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length is 7604 characters, which is substantive and not a mere announcement or certification, but the content is clearly a registration statement, not a financial report or other specific filing type.
2023-01-25 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.